Hepatic Dysfunction and Ketoconazole Therapy

Letters and Corrections1 June 1982Hepatic Dysfunction and Ketoconazole TherapyELSE SVEJGAARD, M.D., LEO RANEK, M.D.ELSE SVEJGAARD, M.D.Search for more papers by this author, LEO RANEK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-6-788_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: A previous communication from our institution described a case of biopsy-proven toxic hepatitis in a patient treated with ketoconazole (1). We recently saw a second patient. Ketoconazole has been widely used (with an estimated 300 000 prescriptions) since it became licensed in the United States in 1981 for treatment of deep mycoses and candidiasis (2). The need for informing physicians of this drug's rare but potentially serious danger is even more acute since the recent advisory from the manufacturer (Janssen Pharmaceutica, Inc., Berse, Belgium) reporting the death of a patient who developed hepatitis during ketoconazole therapy (2)....References1. HEIBERGSVEJGAARD JE. Toxic hepatitis during ketoconazole treatment. Br Med J. 1981;283:825-6. CrossrefMedlineGoogle Scholar2. HUEBNER G. Advisory on hepatocellular dysfunction associated with ketoconazole therapy. 1 March 1982. Available from Janssen Pharmaceutica, Inc., Berse, Belgium. Google Scholar3. PETERSENALLINGKIRKPATRICK EDC. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med. 1980;93:791-5. LinkGoogle Scholar4. FIREBRACE D. Hepatitis and ketoconazole therapy [Letter]. Br Med J. 1981;283:1058-9. CrossrefMedlineGoogle Scholar5. ROBERTSONRICHPARKERHANIFIN MPFJ. Ketoconazole in griseofulvin-resistant dermatophytosis. J Am Acad Dermatol. 1982;6:224-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rigshospital, University of Copenhagen Copenhagen, Denmark PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntifungal agents and liver toxicity: a complex interactionHepatic Safety of Voriconazole after Allogeneic Hematopoietic Stem Cell TransplantationHepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent bindingHEPATOTOXICITY OF ANTIMICROBIAL, ANTIFUNGAL, AND ANTIPARASITIC AGENTSAntifungal agents: An overview. Part IKetoconazole-induced fulminant hepatitis necessitating liver transplantationFungal Infections in the Compromised HostFungal Infections in the Compromised HostHepatic reactions associated with ketoconazole in the United Kingdom.Ketoconazole-associated hepatic injuryLong-term Ketoconazole Treatment of Chronic Acral Dermatophyte InfectionsLong-term Ketoconazole Treatment of Chronic Acral Dermatophyte InfectionsKetoconazole: An Orally Effective Antifungal Agent Mechanism of Action, Pharmacology, Clinical Efficacy and Adverse EffectsHepatic Injury Associated With Ketoconazole TherapyAntifungal drugsKetoconazoleKetoconazole treatment of nail infection in chronic mucocutaneous candidiasisTreatment of chromomycosis with ketoconazole and 5-fluorocytosine 1 June 1982Volume 96, Issue 6_Part_1Page: 788-789KeywordsCandidiasisDrug therapyHepatitis AMycoses ePublished: 1 December 2008 Issue Published: 1 June 1982 PDF downloadLoading ...